Wholly owned Nippon Shinyaku subsidiary developing and commercializing rare-disease medicines, including DMD exon-skipping programs.
Profile review: 2026-11-07 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
VILTEPSO received US accelerated approval based on increased muscle dystrophin; continued approval may depend on confirmatory clinical-benefit evidence.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| VILTEPSO / viltolarsen | DMD exon 53 · DMD amenable to exon 53 skipping | 美国加速批准；2020-08-12 | See original evidence scope |
| NS-089 / NCNP-02 (brogidirsen) | DMD exon 44 · DMD | Phase 2；公司管线页 | See original evidence scope |
| NS-050 / NCNP-03 | DMD exon 50 · DMD | Phase 1/2；公司管线页 | See original evidence scope |
| NS-051 / NCNP-04 | DMD exon 51 · DMD | Preclinical；公司管线页 | See original evidence scope |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Vir Biotechnology announced that Phase 3 ECLIPSE 1 results for elebsiran plus tobevibart in chronic hepatitis delta will be presented on November 8, with an investor discussion on November 9. Elebsiran is an HBV-targeting siRNA; tobevibart is an antibody. The release announces the forthcoming readout and expanded Phase 2 presentations but does not disclose the Phase 3 numerical results.
Nitto Denko Avecia and EnPlusOne signed an evaluation agreement for the ezRNA enzymatic synthesis platform. The phased program covers proof-of-concept studies, laboratory process evaluation, and technology transfer at Avecia facilities. The platform uses a water-based, template-free process. The agreement evaluates manufacturing feasibility; it does not announce a completed commercial manufacturing contract or a definitive platform license.
IDT and Aldevron launched PE Ultra prime-editor mRNA, chemically modified pegRNAs, and six ABE8e-based editor mRNAs with a parallel screening kit. The companies also described guide-design support and stocked quantities from 20 micrograms to 1 milligram. These are research-use products; the announcement does not establish clinical safety, efficacy, or approval.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.